Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS8663 20/5 mg in Chinese patients with mild to moderate primary hypertension
CTR20140715Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olmesartan medoxomil + amlodipine in essential hypertension, sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2014; status: completed.
02
Drugs
olmesartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20140715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140715.